Restricted Versus Liberal Fluid Intake for Prevention of Bronchopulmonary Dysplasia
Launched by UNIVERSITY CHILDREN'S HOSPITAL BASEL · Apr 23, 2025
Trial Information
Current as of June 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how different amounts of fluid intake might affect the health of premature infants, specifically those born before 30 weeks of pregnancy. Researchers want to find out if giving less fluid (about 135 mL per kilogram of body weight per day) compared to more fluid (about 165 mL per kilogram) can help reduce the risk of bronchopulmonary dysplasia (BPD), a serious lung condition, by the time these babies reach 36 weeks of development or if they pass away before that time.
To participate in this study, infants need to be hospitalized and born before 30 weeks of gestation. However, babies with certain health issues, such as serious heart problems or conditions that might affect their lung function or development, won't be eligible. If families choose to participate, they will be part of a study to see how these different fluid amounts impact their baby's health over time. The trial is not yet recruiting participants, but it aims to provide important insights into caring for very premature babies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hospitalised preterm infants born before 30 weeks 0 days gestation
- • Signed informed consent for further research use of health-related data
- Exclusion Criteria:
- • congenital malformations
- • diseases likely to affect life expectancy, lung function, fluid strategy, or neurodevelopment
- • renal disease requiring fluid management outside the clinical standard of care
- • congenital heart disease not including patent ductus arteriosus (PDA)
About University Children's Hospital Basel
The University Children's Hospital Basel is a leading pediatric healthcare institution committed to advancing child health through innovative research and clinical excellence. As a prominent clinical trial sponsor, the hospital focuses on developing and evaluating new therapies and interventions tailored to the unique needs of children. With a multidisciplinary team of experienced pediatricians, researchers, and healthcare professionals, the hospital fosters a collaborative environment that prioritizes patient safety and ethical standards. By engaging in cutting-edge clinical trials, the University Children's Hospital Basel aims to enhance treatment options and improve outcomes for pediatric patients, contributing to the broader field of child health and medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Luzern, , Switzerland
Basel, , Switzerland
Aarau, , Switzerland
Bern, , Switzerland
Chur, , Switzerland
Genève, , Switzerland
St. Gallen, , Switzerland
Zürich, , Switzerland
Patients applied
Trial Officials
Sven Schulzke, Prof.MD
Principal Investigator
University Children's Hospital Basel, UKBB
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported